| Similar Articles |
|---|
 |
The Motley Fool
March 19, 2009
Brian Orelli |
Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too.   |
The Motley Fool
April 5, 2011
Cindy Johnson |
Cubist Pharmaceuticals Shares Popped: What You Need to Know Cubist Pharmaceuticals popped as much as 17% in intraday trading today after announcing a licensing agreement and the settlement of a patent dispute. |
The Motley Fool
November 2, 2010
Travis Hoium |
Momenta Pharmaceuticals Shares Plunged: What You Need to Know Momenta Pharmaceuticals shares fell 10% in trading early Tuesday after Teva Pharmaceutical Industries said it expects FDA approval this year on a drug to compete with Momenta's enoxaparin. |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma. |
The Motley Fool
November 27, 2006
Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. |
The Motley Fool
October 5, 2011
Dan Caplinger |
Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future. |
The Motley Fool
April 7, 2010
Rick Steier |
Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity. |
The Motley Fool
May 3, 2007 |
Teva Pharmaceutical Has Strong Quarter: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
July 14, 2006
Stephen D. Simpson |
The Diverging Fortunes of Forest and Teva If a patent ruling holds up, Forest's prospects are much stronger. Unfortunately, the easy money has long since been made in Forest and today's announcement will almost certainly mean another big jump in the stock price. |
The Motley Fool
November 1, 2005
Stephen D. Simpson |
Belly Up to Barr Though not cheap, this is a high-quality generic drug company. However, investors must do their own due diligence and decide for themselves whether today's price offers enough margin of safety for a sound investment. |
The Motley Fool
June 6, 2005
Stephen D. Simpson |
"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position. |
The Motley Fool
May 9, 2006
Stephen D. Simpson |
Will Par Stay in the Fairway? Par Pharmaceutical is relatively unloved; does that mean opportunity or inferiority for investors? |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
July 29, 2011
Cindy Johnson |
Applied Micro Circuits Shares Plunged: What You Need to Know Applied Micro Circuits dropped 17% in intraday trading today after reporting an inline quarter with disappointing gross margins. Is this meaningful? Or just another movement? |
The Motley Fool
July 28, 2011 |
Medicis Pharmaceutical Earnings Preview Medicis Pharmaceutical will unveil its latest earnings on Tuesday, August 2. |
The Motley Fool
February 4, 2008
Chuck Saletta |
Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker. |
The Motley Fool
April 25, 2011
Sean Williams |
Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing. |
The Motley Fool
October 18, 2010
Brian Orelli |
Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs. |
The Motley Fool
November 3, 2010
Brian Orelli |
Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits. |
The Motley Fool
October 29, 2007
Brian Orelli |
The Extended Release That Wasn't The FDA is investigating Teva's generic version of Wellbutrin XL. Investors, take note. |
The Motley Fool
August 1, 2005
Stephen D. Simpson |
Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance. |
The Motley Fool
November 29, 2010
Seth Jayson |
Here's How Teva Pharmaceutical May Be Failing You Here's the margin picture for Teva Pharmaceutical over the past few years. |
The Motley Fool
November 26, 2008
Brian Orelli |
Teva and AstraZeneca's Drama Concludes Teva and AstraZeneca settle a lawsuit, but investors are still left in the dark. |
The Motley Fool
February 13, 2008
Brian Orelli |
Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted. |
The Motley Fool
March 3, 2004
Alyce Lomax |
Biovail Gets Nailed... Again The Canadian drug maker's stock falls on downbeat guidance. |
The Motley Fool
November 8, 2005
Stephen D. Simpson |
Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares? |
The Motley Fool
December 26, 2007
Brian Orelli |
Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute. |
The Motley Fool
November 5, 2004
Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
The Motley Fool
May 10, 2006
Stephen D. Simpson |
Time to Make Room for Teva? This might be a rare chance to pick up a dominant company at an attractive price. Investors, take note. |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
A More Realistic Bar for Barr Labs An unpleasant, but not altogether unexpected drop makes this generic drug company and better value for investors. |
The Motley Fool
April 7, 2010
Brian Orelli |
Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious. |
The Motley Fool
April 14, 2008
Brian Orelli |
Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal. |
The Motley Fool
September 22, 2009
Robert Steyer |
Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge. |
The Motley Fool
January 19, 2010
Brian Orelli |
Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious. |
The Motley Fool
November 2, 2010
Eric Dutram |
Tuesday's ETF to Watch: iShares Israel ETF (EIS) TEVA reports earnings. |
The Motley Fool
June 11, 2008
Brian Orelli |
Mylan Takes Generic Aim at Teva Mylan licenses a generic version of Teva's MS drug, Copaxone. Investors, take note. |
The Motley Fool
December 20, 2010
Seth Jayson |
Should You Get Out of Medicis Pharmaceutical Before Next Quarter? The numbers don't paint a clear picture. For the last fully reported fiscal quarter, Medicis Pharmaceutical's year-over-year revenue grew 16.8%, and its AR grew 138.1%. That's a yellow flag. |
The Motley Fool
January 2, 2004
Dave Marino-Nachison |
Medicis: Skin Is In The drug maker has a strong balance sheet and a commitment to product development. |
The Motley Fool
October 30, 2010 |
Motley Fool Battle Royale Final Round: Teva Pharmaceutical vs. VMware In final round, to-the-death stock match-up, the Israeli generic drug giant Teva Pharmaceutical faces VMware, a successful software firm that is turning cloud-based solutions into big business. Which stock will emerge as the ultimate victor? |
The Motley Fool
February 21, 2008
Brian Orelli |
Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company. |
The Motley Fool
August 15, 2006
Stephen D. Simpson |
Twirling the Barr Look closely and you'll see that Barr posted a solid quarter. Investors, if you haven't checked this one out yet, now may be the time for a little due diligence. |
The Motley Fool
October 12, 2010
Selena Maranjian |
Don't Underestimate These Great Stocks Companies with rock-bottom P/Es could be true bargains. |
The Motley Fool
April 13, 2010
Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
The Motley Fool
May 21, 2009
Brian Orelli |
If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did. |
The Motley Fool
December 14, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Piper Jaffray plays a wrong note on Teva. |
The Motley Fool
January 15, 2008
Brian Orelli |
Fewer Generics in Fido's Future TEVA considers selling its small animal-health business. |
BusinessWeek
April 15, 2010
Naomi Kresge |
As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags. |
The Motley Fool
June 17, 2008
Brian Orelli |
Change a Label, Change the Game For Teva Pharmaceutical, swapping the label on its Parkinson's drug, Azilect, could add hundreds of millions of dollars in sales per year. |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
